(Q59074825)

13 March 2019

25 April 2019

17 June 2019

1 August 2019

20 November 2019

27 November 2019

1 February 2021

on focus list of Wikimedia project

28 October 2022

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Juvenile dermatomyositis: new insights and new treatment strategies.

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy.

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab.

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

A randomized, pilot trial of etanercept in dermatomyositis

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies.

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

High frequencies and co-existing of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies overlapped to rheumatoid arthritis

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Antisynthetase syndrome presenting as rheumatoid-like polyarthritis

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Tumor necrosis factor inhibitor-associated dermatomyositis

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Development of antisynthetase syndrome in a patient with rheumatoid arthritis

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Thrombocytopenia associated with the use of anti-tumor necrosis factor-alpha agents for psoriasis

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Autoimmune diseases induced by TNF-targeted therapies

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Inflammatory molecules: a target for treatment of systemic autoimmune diseases

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Tumour necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Treatment of early and refractory dermatomyositis with infliximab: a report of two cases

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1.

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Association of polymyositis with rheumatoid arthritis

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Adverse drug reactions: definitions, diagnosis, and management

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases

30 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926249

Is dermatomyositis in patients with rheumatoid arthritis induced by anti-TNF-α therapy?

30 November 2018

1 reference

12 December 2020

Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis

1 reference

12 December 2020

Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis

1 reference

12 December 2020

Paradoxical reactions to targeted biological treatments: A way to treat and trigger?

1 reference

12 December 2020

Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor

1 reference

12 December 2020

Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis

1 reference

12 December 2020

Anticyclic citrullinated peptide antibodies as markers of erosive arthritis in antisynthetase syndrome

1 reference

12 December 2020

Dermatomyositis during adalimumab therapy for rheumatoid arthritis

1 reference

12 December 2020

Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients

1 reference

12 December 2020

Antisynthetase syndrome associated with long-standing rheumatoid arthritis

1 reference

12 December 2020

Refractory polymyositis responding to infliximab

1 reference

12 December 2020

Polymyositis associated with infliximab treatment for rheumatoid arthritis

1 reference

12 December 2020

Neuromuscular involvement in rheumatic patients treated with anti-tumor necrosis factor therapy--three examples

1 reference

12 December 2020

Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab

1 reference

12 December 2020

Destructive arthropathy associated with dermatomyositis sine myositis positive for anti-Jo-1 and anti-cyclic citrullinated peptide antibodies

1 reference

12 December 2020

Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis

1 reference

12 December 2020

A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept

1 reference

12 December 2020

Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis

1 reference

12 December 2020

Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma

1 reference

12 December 2020

Polymyositis associated with infliximab treatment for rheumatoid arthritis

1 reference

12 December 2020

A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies

1 reference

12 December 2020

Use of etanercept in the treatment of dermatomyositis: a case series

1 reference

12 December 2020

Etanercept as steroid-sparing agent in dermatomyositis

1 reference

12 December 2020

[Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center]

1 reference

12 December 2020

Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab

1 reference

12 December 2020